Navigation Links
Indevus Announces Submission of New Drug Application
Date:8/28/2007

une 2007, reflecting the world-wide experience from over 260,000 injections of NEBIDO.

"The submission of the NEBIDO NDA is a very important milestone for the Company," said Glenn L. Cooper, M.D., chief executive officer and chairman of Indevus. "We strongly believe that NEBIDO can greatly improve the treatment options for men who suffer from hypogonadism."

Phase III Pharmacokinetic Trial

In June 2007, the Company announced positive results of its Phase III pharmacokinetic trial with NEBIDO. The purpose of the trial was to evaluate NEBIDO under U.S. Food and Drug Administration (FDA) pharmacokinetic guidelines for the approval of testosterone therapy products for male hypogonadism. The trial met its primary endpoints: a responder analysis based on the average testosterone concentrations during the steady-state dosing interval and an outlier analysis based on the maximum testosterone concentrations during the steady-state dosing interval.

Phase III Study Design

The Phase III pharmacokinetic trial was a randomized open-label (unblinded) study that included the evaluation of the pharmacokinetics of NEBIDO dosed as either 1000 mg every 12 weeks or as 750 mg every 12 weeks, both via intramuscular injection. The primary endpoints included a responder analysis (based on guidelines provided from the FDA for average testosterone concentrations over the steady state dosing interval) and an outlier analysis (based on the maximum testosterone concentrations during the steady state dosing interval). Specifically, a responder was defined (per the FDA) as a patient who, at steady-state conditions, had an average concentration of serum total testosterone (Cavg) within the normal range (300 to 1000 ng/dL). The primary response endpoint was met if at least 75% of patients achieved a Cavg within this normal range. FDA also provided guidelines related to maximum testosterone (Cmax) levels, including thresholds that no patient should exceed a testosterone c
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Indevus Announces Presentation of Pagoclone Data at 47th Annual New Clinical Drug Evaluation Unit Meeting
2. Indevus Reports Positive Data From Phase III NEBIDO Trial
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- Israel Brain Technologies (IBT) has announced the ... 1 st International Brain Technology Conference, which ... in Tel Aviv , recently ranked as ... by the Wall Street Journal and the epicenter ... showcase the latest breakthroughs in neuroscience and brain technology and ...
(Date:5/23/2013)... May 23, 2013 Halozyme Therapeutics, Inc. ... appointment of David A. Ramsay ... most recently Vice President, Corporate Development at Halozyme. ... "With his established financial management experience and ... working in our commercial group for the last ...
(Date:5/23/2013)... 2013  Omeros Corporation (NASDAQ: OMER ... Application (IND) to evaluate OMS824 in Huntington,s disease ... Drug Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 ... brain linked to a wide range of diseases ... OMS824 has shown promising results in animal models ...
Breaking Medicine Technology:Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4
... Whenever someone needs high-quality drugs for less money, they are ... of the large choice of pharmacies, it may not be ... make things simpler and safer for anyone looking to buy ... website promotion is the responsibility of the renowned search ...
... 2011 /PRNewswire-Asia/ -- Winner Medical Group Inc. (Nasdaq: ... manufacturer of medical dressings, medical disposables and non-woven ... China, today announced that one of its subsidiaries, ... recently awarded a Cotton Processing Certificate by the ...
Cached Medicine Technology:New Online Pharmacy Rx-webmasters.com Allows Customers to Pay Less for High-Quality Drugs 2Winner Medical Obtains Cotton Processing Certificate from the State Development and Reform Commission 2Winner Medical Obtains Cotton Processing Certificate from the State Development and Reform Commission 3
(Date:5/23/2013)... Rottenstein Law Group LLP, a New York-based nationwide mass ... Center at http://www.rotlaw.com/tylenol , dedicated to issues that ... filing lawsuits. , The painkiller Tylenol (acetaminophen) has ... to a 2009 report from the U.S. Food and ... warned consumers against using more than the recommended dose ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Dr. Katherine ... new charitable organization in Orange County, OCCares , will ... Orange County. The event details are as follows: , ... Academy Auditorium, 13732 Clinton Street, Garden Grove, CA 92843 , ... crossover music by Christian vocalists Charmaine & Jonathan Thulin. ...
(Date:5/23/2013)... The vast majority of Americans believe it’s ... their level of physical activity, the healthfulness of their ... taking that control. Those are among the findings ... Food & Health Survey. , According to the Survey, ... “a great deal of control” or “complete control” over ...
(Date:5/23/2013)... 2013 Click here to read the ... are increasingly seeing their success develop through merger ... according to new research carried out by MaRS ... company has compiled its research into a series of ... the research have shown the general trend that the ...
(Date:5/23/2013)... 2013 Jeanne Ettelson, president of ... popular and only free OCD support group in Chicago. ... for OCD sufferers, the group is lead by psychologists ... This allows group participants to learn accurate information ... Prevention. , “Participants in Beyond OCD’s support group ...
Breaking Medicine News(10 mins):Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 2Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 3Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 4Health News:Beyond OCD Support Group Marks Fifth Anniversary 2
... a protein called IGF-1 not entirely successful, studies find ... that prostate cancer can be treated successfully just by ... factor (IGF-1) has been undermined by two new studies. ... a number of drug companies and academic researchers, stimulated ...
... Consumers flooded Castle Connolly,s,website http://www.castleconnolly.com in ... Top Doctors," offered in collaboration with the,award-winning newspaper ... alone,Tuesday, April 29th, Newsday,s online users viewed Castle ... to our usual heavy traffic,from other sources," said ...
... MIRAMAR, Fla., May 1 Nipro Diabetes Systems ... time to the market. The,pump helps control blood ... and 2,diabetes. Built for safety, reliability, accuracy and ... screens for easy programming.,Developed and manufactured in the ...
... to Make Ends Meet, HARRISBURG, Pa., May 1 ... the rising costs of health care,would be greatly helped ... care insurance for all, a Department of Agriculture official ... Food Bank, Deputy Secretary,of Agriculture Cheryl Cook said passage ...
... 1 Physicians Healthcare Management,Group, Inc. (Phyhealth) ... organizations (HMOs) in partnership with physicians, today,announced ... as medical director,of Phyhealth Plan Corporation., ... Orlando, Florida, who has,extensive experience as the ...
... with pregnancy outcomes, CHICAGO, May 1 With ... wants to remind mothers-to-be,that maintaining good oral health is ... Research suggests there may be an association between maternal ... In addition, a,recent study says that pregnant women with ...
Cached Medicine News:Health News:Complications Found in Proposed Prostate Cancer Treatment 2Health News:Castle Connolly's 'Long Island's Top Doctors' Published in Newsday Generates More Than 1.1 Million Views of Top Doctors' Profiles in Single Day 2Health News:Photo: Introduction of the Amigo Insulin Pump Offers a Lifestyle Where 'Life Has No Limits' 2Health News:Pennsylvania Agriculture Official Says Passage of PA ABC Crucial to Rural Communities 2Health News:Phyhealth Appoints Gerald H. Priceman as Medical Director 2Health News:Phyhealth Appoints Gerald H. Priceman as Medical Director 3Health News:American Dental Association Stresses Good Oral Health During Pregnancy 2
Solid 14 mm blades. Dull finish....
Angled for temporal approach. Open 14 mm rounded blades for patient comfort. Dull finish....
Open 14 mm blades of heavy 1 mm wire. Dull finish. Most popular size or model....
Open wire style blades allow complete manipulation of the phaco tip inside the eye. Lid control is excellent, exposure is maximized, and the likelihood of positive pressure is reduced....
Medicine Products: